We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals
NRXP

18 hedge funds and large institutions have $39.2M invested in NRX Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

69% more capital invested

Capital invested by funds: $23.1M → $39.2M (+$16.1M)

20% more funds holding

Funds holding: 15 → 18 (+3)

4.84% less ownership

Funds ownership: 9.37% → 4.53% (-4.8%)

Holders
18
Holders Change
+3
Holders Change %
+20%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
9
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFM
Boothbay Fund Management
New York
+$5.26M
2
BI
Bulldog Investors
New Jersey
+$2.45M
3
WCMNY
Westchester Capital Management (New York)
New York
+$2.39M
4
WAM
Weiss Asset Management
Massachusetts
+$2M
5
KIM
Karpus Investment Management
New York
+$1.56M

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$120K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$5.3M +$5.26M +53,953 New
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$4.23M – – –
HIM
3
HGC Investment Management
Ontario, Canada
$4.18M +$198K +2,034 +5%
WAM
4
Weiss Asset Management
Massachusetts
$3.75M +$2M +20,560 +117%
OAM
5
Oxford Asset Management
United Kingdom
$2.78M +$731K +7,500 +36%
KIM
6
Karpus Investment Management
New York
$2.47M +$1.56M +16,039 +176%
BI
7
Bulldog Investors
New Jersey
$2.46M +$2.45M +25,151 New
WCMNY
8
Westchester Capital Management (New York)
New York
$2.4M +$2.39M +24,476 New
WRBC
9
W.R. Berkley Corp
Connecticut
$1.98M +$336K +3,451 +21%
AA
10
AQR Arbitrage
Connecticut
$1.95M – – –
GCL
11
Glazer Capital LLC
New York
$1.87M – – –
YCM
12
Yakira Capital Management
Connecticut
$1.62M – – –
PC
13
Periscope Capital
Ontario, Canada
$1.49M +$983K +10,080 +200%
KPF
14
K2 Principal Fund
Ontario, Canada
$1.43M +$694K +7,121 +95%
DAM
15
Deltec Asset Management
New York
$732K – – –
BCM
16
Basso Capital Management
Connecticut
$526K +$35.1K +360 +7%
BCM
17
Bluefin Capital Management
New York
$33K +$211K +2,160 +27%
UBS Group
18
UBS Group
Switzerland
$13K +$12.7K +130 New
VF
19
Virtu Financial
New York
– -$120K -1,241 Closed

NRXP Hedge Fund Activity: Q1 2018 in Review

18 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2018, worth a combined $39.2M — up 69% from $23.1M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NRXP positions and 1 closed out — a net gain of 3 holders — while 9 added to existing stakes and 0 trimmed.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $5.26M. The largest seller was Virtu Financial, exiting entirely with an estimated $120K sold.

  • 18 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2018, up from 15 in Q4 2017.
  • Funds reported $39.2M of NRX Pharmaceuticals stock for Q1 2018, up 69% quarter-over-quarter.
  • 4 funds opened new NRX Pharmaceuticals positions in Q1 2018 and 1 closed out, a net change of +3 holders.
  • The largest NRX Pharmaceuticals buyer in Q1 2018 was Boothbay Fund Management, an estimated $5.26M added.
  • The largest NRX Pharmaceuticals seller in Q1 2018 was Virtu Financial, an estimated $120K sold.

Based on aggregated 13F filings for Q1 2018.